Direxion Daily Biotech Top 5 Bull 2X ETF

TBXU

Valor de mercado US$ 4,82 mi

In October 2025, Direxion Investments welcomed a new family of ETFs into their ever-growing roster of leveraged and inverse funds: the Titans ETFs. The suite of funds essentially give traders a middle ground when deciding between broad sector exposure and single-stock opportunities.

In October 2025, Direxion Investments welcomed a new family of ETFs into their ever-growing roster of leveraged and inverse funds: the Titans ETFs. The suite of funds essentially give traders a middle ground when deciding between broad sector exposure and single-stock opportunities.

Biotech stocks could sway toward the upside with the appointment of a new director at the Federal Drug Administration's Center for Drug Evaluation and Research. Dr. Richard Pazdur will take the reigns, bringing 26 years of related industry experience.

Direxion expanded its existing product lineup of leveraged and inverse exchange-traded funds (ETFs) with a new suite: the Titans Leveraged & Inverse ETFs. The funds offer a middle-ground approach that eschews the concentration risk inherent in single-stocks ETFs.

New York, United States, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Direxion, a leading provider of tactical ETFs, today announced the launch of the Direxion Titans Leveraged & Inverse ETFs, a new suite of funds designed to give active traders precise exposure to the top five companies in key U.S. sectors and industries.